tbResList Print — DCA Dichloroacetate

Description: <b>Dichloroacetate (DCA)</b> is a metabolic modulator that targets the altered metabolic state of cancer cells by inhibiting PDKs. This action impacts several key pathways:<br>
<br>
• Reversal of the Warburg effect<br>
• Restoration of mitochondrial function and promotion of apoptosis<br>
• suppresses glycolysis and promotes oxidative phosphorylation, thereby increasing mitochondrial ROS-mediated apoptosis in tumor cells
• Increase in ROS production leading to oxidative stress<br>
• Inhibition of cell cycle progression<br>
• Modulation of HIF-1α signaling: DCA might decrease HIF-1α stabilization, thereby reducing the expression of genes that support glycolysis, angiogenesis, and survival under low-oxygen conditions.<br>
<br>
-DCA has been primarily used in treating congenital lactic acidosis—a rare genetic disorder characterized by the buildup of lactic acid in the body.<br>
-DCA is an experimental anti-diabetic and lipid-lowering drug, as well as treating myocardial and cerebrovascular ischemia.<br>
<br>
-Do not add DCA to hot or warm beverages(theorical). DCA is unstable at higher temperatures<br>
-Caffeinated may increase effectiveness<br>
-Vitamin B1 reduces neuropathy (500mg-2500mg/day)<br>
-Possibly 20 grams of citric acid 20 minutes before taking DCA<br>
-Procaine, Diclofenac or Sulindac may increase SMCT1 <br>
-Omeprazole 80mg/day to increase DCA effectiveness<br>
-Scorpion venom to increase DCA effectiveness <br>
-Metformin 1000mg to 1500mg/day<br>
-Propranolol (Ref.)<br>
-Fenbendazole shows strong synergy when combined to DCA, So it may make very much sense to combine the two.<br>
<a href="https://www.cancertreatmentsresearch.com/dichloroacetate-dca-treatment-strategy/">
"Note: DCA is not tumor cell specific,> and therefore the same shift in glucose metabolism that occurs in cancer cells will also take place in immune cells, leading to induction of Tregs (Ref.). In order to avoid this possibility, while using DCA I would also use Treg inhibitors such as Cimetidine (Ref.) or low dose Cyclophosphamide (Ref.)." </a><br>
<a href="https://www.preprints.org/manuscript/202403.0254">"DCA should not be used in association with allopurinol, NSAIDs, or flavonoids because they reduce cellular DCA uptake."</a><br>
<a href="https://www.preprints.org/manuscript/202403.0254">"triple association of DCA, metformin and celecoxib, which has never been experimentally tested in patients, deserves well planned phase II clinical trials"</a><br>

<br>
Research Dose: 10mg/kg/day and increase slowly to about 25mg/kg/day:(1/2morn,1/2evening) take 5 days on, 2 off? OR 2wks on/ 1wk off: https://www.thedcasite.com/dca_dosage.html</a><br>
Done by mixing it in water and drinking, suggested that DCA not be taken on an empty stomach.<br>
<br>
**** <br>
DCA-induced apoptosis in cancer cells requires sodium-coupled monocarboxylates transporter SLC5A8 (SMCT1)<br>
-Inhibitors of DNA methylation induce reactivation of SLC5A8<br>
-Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells.<br>
-SMCT1 was found to be stimulated by some other NSAIDs (diclofenac, meclofenamate and sulindac), by activin A143 and by the probiotic Lactobacillus plantarum. <br>
<br>
<a href="https://www.sciencedirect.com/science/article/pii/S2444866416300034"> SMCT1 has been found to be inhibited by some NSAIDs (ibuprofen, ketoprofen, fenoprofen, naproxen135 and indomethacin94), phytochemicals (resveratrol and quercetin) </a> **** Hence these should be avoided with DCA(theorical). (also theorically AVOID Bromide, iodide and sulfite )<br>
<br>
****<br>
GSTZ1 an/or chloride anion transport inhibitors also reduce resistance to DCA
(if the tumor expresses GSTZ1 and contains a high chloride anions level, the GSTZ1 will be stable, maintaining the resistance to DCA).<br>
<br>
-<a href="https://www.cancertreatmentsresearch.com/">Dichloroacetate-dca-treatment-strategy </a>GSTZ1 an/or chloride anion transport inhibitors. .<br>
-<a href="http://www.ncbi.nlm.nih.gov/pubmed/1839837">Etacrynic acid is a Cl(-)-ATPase inhibitor </a> <br>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/10711360">-Lansoprazole and Omeprazole inhibit chloride channels. </a><br>
-<a href="https://en.wikipedia.org/wiki/Chlorotoxin">Chlorotoxin found in scorpion venom (see my post on scorpion venom) can also inhibit chlorine channels </a> <br>
<br>
Sources:<br>
<a href="https://northernhealthproducts.com/shop/" >https://northernhealthproducts.com/shop/</a> <br>
<a href="https://www.dcalab.com/">https://www.dcalab.com/ </a> <br>
<a href="https://ccnm.edu/sites/default/files/2025-10/DCA%20-professional-Sept2025.pdf"> Excellent DCA review </a> <br>
<br>

<p><b>Dichloroacetate</b> — Dichloroacetate, usually administered as sodium dichloroacetate, is a small-molecule metabolic modulator that inhibits pyruvate dehydrogenase kinases and thereby activates the mitochondrial pyruvate dehydrogenase complex. It is formally classified as an investigational metabolic drug and pyruvate dehydrogenase kinase inhibitor. DCA is a synthetic chlorinated acetate historically investigated for congenital mitochondrial and lactic-acidosis disorders; it is not an approved anticancer therapy. Its principal translational limitation is the narrow separation between concentrations that alter tumor metabolism and chronic exposures associated with peripheral neuropathy.</p>

<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Inhibition of PDK isoenzymes, especially PDK2, causing ↓ inhibitory PDH phosphorylation and ↑ pyruvate entry into mitochondrial oxidation.</li>
<li>Partial reversal of the Warburg phenotype through ↓ lactate-producing glycolytic flux and ↑ mitochondrial oxidative phosphorylation.</li>
<li>Remodeling of cancer-cell mitochondrial membrane potential and restoration of intrinsic apoptotic susceptibility.</li>
<li>↑ mitochondrial ROS and oxidative stress in susceptible cancer cells, particularly under hypoxic or treatment-stressed conditions.</li>
<li>Attenuation of the HIF-1α–PDK metabolic adaptation to hypoxia, with context-dependent effects on tumor oxygenation and treatment resistance.</li>
<li>Radiosensitization and chemosensitization through metabolic reprogramming, increased oxidative stress, altered autophagy and reduced hypoxia-associated resistance.</li>
<li>Context-dependent modulation of Kv1.5, intracellular K⁺, NFAT and Ca²⁺-linked apoptotic signaling.</li>
</ol>

<p><b>Bioavailability / PK relevance:</b> Oral DCA is systemically bioavailable, but its pharmacokinetics are nonlinear and time-dependent. DCA is metabolized primarily by GSTZ1, while DCA also irreversibly inhibits GSTZ1, producing reduced clearance and progressive drug accumulation during repeated exposure. GSTZ1 genotype, age and treatment duration can substantially alter plasma exposure. Chronic exposure is limited principally by reversible or incompletely reversible peripheral sensory and motor neuropathy; gastrointestinal, hepatic and hematologic adverse effects have also been reported.</p>

<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer studies use approximately 1–20 mM DCA, frequently 5–20 mM. Sustained human plasma concentrations at the upper end of this range are generally not achievable without substantial toxicity. Clinical PK data indicate that tolerated concentrations may inhibit constitutive PDK2 but may be inadequate for less-sensitive or highly induced PDK isoforms. Consequently, strong cytotoxicity observed at high millimolar concentrations should not be assumed to translate directly to patients.</p>

<p><b>Clinical evidence status:</b> Extensive preclinical evidence; several small phase I and phase II human studies; one randomized placebo-controlled phase II adjunct study with cisplatin chemoradiotherapy; no phase III validation and no regulatory approval for cancer. Early trials demonstrate measurable metabolic effects and generally manageable short-term administration, but objective anticancer efficacy remains inconsistent and unproven. A randomized head-and-neck cancer study did not establish a clear survival advantage, while reporting increased low-grade fever and thrombocytopenia. DCA remains an investigational adjunct rather than a standard anticancer treatment.</p>

<br>
<h3>Dichloroacetate Mechanistic Profile</h3>
<table border="1" cellspacing="0" cellpadding="4">
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PDK inhibition and PDH activation</td>
<td>↓ PDK activity<br>↓ p-PDH<br>↑ active PDH</td>
<td>↓ PDK activity<br>↑ glucose oxidation</td>
<td>P–G</td>
<td>Redirects pyruvate toward acetyl-CoA and mitochondrial oxidation</td>
<td>Canonical mechanism. PDK2 is relatively sensitive; inhibition of other PDK isoforms may require higher exposure.</td>
</tr>
<tr>
<td>2</td>
<td>Warburg metabolism and glycolysis</td>
<td>↓ glycolytic dependence<br>↓ ECAR<br>↓ lactate production</td>
<td>Variable metabolic shift</td>
<td>R–G</td>
<td>Reduces fermentative glucose metabolism and extracellular acidification</td>
<td>Effect magnitude depends on PDK expression, mitochondrial competence, substrate availability and tumor lineage.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial respiration</td>
<td>↑ pyruvate oxidation<br>↑ OCR<br>↑ OXPHOS</td>
<td>↑ glucose oxidation<br>↑ mitochondrial workload</td>
<td>R–G</td>
<td>Restores mitochondrial use of glucose-derived carbon</td>
<td>Increased respiration is not intrinsically cytotoxic and can support survival in metabolically flexible tumors.</td>
</tr>
<tr>
<td>4</td>
<td>Mitochondrial membrane potential and apoptosis</td>
<td>↓ pathological hyperpolarization<br>↑ cytochrome c release<br>↑ caspase activation</td>
<td>Usually less pronounced</td>
<td>R–G</td>
<td>Lowers the threshold for intrinsic apoptosis</td>
<td>Strongest in models with cancer-associated mitochondrial hyperpolarization; not universal across tumor types.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial ROS increase</td>
<td>↑ mt-ROS<br>↑ oxidative damage (context-dependent)</td>
<td>↔ or ↑ ROS with prolonged exposure</td>
<td>R–G</td>
<td>Produces redox stress and apoptotic sensitization</td>
<td>ROS direction is model-dependent. Increased respiration can raise ROS, but improved electron flow may reduce ROS in some systems.</td>
</tr>
<tr>
<td>6</td>
<td>HIF-1α and hypoxic adaptation</td>
<td>↓ HIF-1α signaling<br>↓ PDK1-mediated adaptation (context-dependent)</td>
<td>Limited evidence</td>
<td>G</td>
<td>Weakens hypoxia-driven glycolysis, survival and treatment resistance</td>
<td>DCA can also increase cellular oxygen consumption; the net effect on tumor hypoxia depends on perfusion and oxygen delivery.</td>
</tr>
<tr>
<td>7</td>
<td>Radiosensitization</td>
<td>↑ radiation sensitivity<br>↑ ROS-mediated injury<br>↓ hypoxic resistance</td>
<td>Potential normal-tissue sensitization (context-dependent)</td>
<td>R–G</td>
<td>Enhances radiation response in selected models</td>
<td>Supported preclinically and evaluated clinically as an adjunct, but a definitive therapeutic benefit has not been established.</td>
</tr>
<tr>
<td>8</td>
<td>Chemosensitization</td>
<td>↑ sensitivity to cisplatin, 5-FU, paclitaxel and selected metabolic agents (model-dependent)</td>
<td>Potential additive toxicity</td>
<td>G</td>
<td>Reduces metabolic and hypoxic drug resistance</td>
<td>Combination effects vary markedly. Preclinical synergy does not establish clinical efficacy or safe dosing.</td>
</tr>
<tr>
<td>9</td>
<td>Autophagy</td>
<td>↑ or ↓ autophagic flux (context-dependent)</td>
<td>Insufficient evidence</td>
<td>G</td>
<td>May promote adaptation or enhance treatment-induced death</td>
<td>Autophagy is bidirectional: DCA-induced autophagy can be protective in some tumors and therapeutically exploitable in others.</td>
</tr>
<tr>
<td>10</td>
<td>Kv1.5 NFAT and Ca²⁺ signaling</td>
<td>↑ Kv1.5<br>↓ intracellular K⁺<br>↓ NFAT activation<br>Ca²⁺ modulation</td>
<td>Variable</td>
<td>R–G</td>
<td>Facilitates apoptotic signaling and suppresses proliferation</td>
<td>Mechanistically important in selected early models but less consistently demonstrated than the PDK–PDH axis.</td>
</tr>
<tr>
<td>11</td>
<td>Transport and metabolic sensitivity</td>
<td>SLC5A8 may ↑ intracellular DCA response<br>GSTZ1 and chloride modify sensitivity</td>
<td>GSTZ1 controls systemic clearance</td>
<td>G</td>
<td>Determines cellular exposure, metabolism and resistance</td>
<td>SLC5A8 dependence is model-specific. GSTZ1 genotype and self-inactivation are clinically important determinants of exposure and neuropathy.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>High millimolar concentrations often required<br>heterogeneous PDK expression<br>metabolic plasticity</td>
<td>Peripheral neuropathy<br>variable clearance<br>possible hepatic and hematologic toxicity</td>
<td>G</td>
<td>Restricts sustained target coverage and therapeutic index</td>
<td>Human exposure may inhibit PDK2 yet remain below concentrations used for broad in-vitro cytotoxicity. DCA is investigational and not an approved cancer treatment.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min&nbsp;&nbsp;&nbsp; R: 30 min–3 hr&nbsp;&nbsp;&nbsp; G: &gt;3 hr</p>
<br><br>




Older Table:
<table border="1" cellspacing="0" cellpadding="4">
<tr>
<th>Rank</th>
<th>Pathway / Target Axis</th>
<th>Direction</th>
<th>Primary Effect</th>
<th>Notes / Cancer Relevance</th>
<th>Ref</th>
</tr>

<tr>
<td>1</td>
<td>Pyruvate dehydrogenase kinase (PDK) → PDH gatekeeper</td>
<td>↓ PDK activity → ↑ active PDH (dephosphorylated)</td>
<td>Warburg reversal (pyruvate into TCA)</td>
<td>DCA’s canonical mechanism: inhibits PDK, restoring PDH activity and oxidative metabolism in cancer</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/20463368/">(ref)</a></td>
</tr>

<tr>
<td>2</td>
<td>Glycolysis output (lactate / ECAR)</td>
<td>↓ lactate production / ↓ ECAR</td>
<td>Reduced acidification; metabolic reprogramming</td>
<td>DCA decreases PDH phosphorylation and lowers glycolytic output (lactate/ECAR) in cancer models</td>
<td><a href="https://www.mdpi.com/1422-0067/21/24/9367">(ref)</a></td>
</tr>

<tr>
<td>3</td>
<td>Mitochondrial membrane potential remodeling (ΔΨm)</td>
<td>↓ cancer-associated mitochondrial hyperpolarization (depolarization)</td>
<td>Restores apoptosis susceptibility</td>
<td>Glioblastoma work: DCA reverses cancer-specific mitochondrial remodeling (hyperpolarization → depolarization), enabling apoptosis</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/20463368/">(ref)</a></td>
</tr>

<tr>
<td>4</td>
<td>ROS generation (especially under hypoxia)</td>
<td>↑ ROS</td>
<td>Oxidative stress trigger</td>
<td>DCA increases ROS in hypoxic cancer cells (reported strongly under hypoxia), linking metabolic shift to cytotoxic stress</td>
<td><a href="https://www.mdpi.com/1422-0067/21/24/9367">(ref)</a></td>
</tr>

<tr>
<td>5</td>
<td>Voltage-gated K+ channel axis (Kv1.5) / NFAT signaling</td>
<td>↑ Kv1.5 expression/activity</td>
<td>Pro-apoptotic electrophysiology shift</td>
<td>Endometrial cancer study: DCA engages mitochondrial + NFAT–Kv1.5 mechanisms associated with apoptosis sensitization</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/18423823/">(ref)</a></td>
</tr>

<tr>
<td>6</td>
<td>Intrinsic apoptosis (mitochondrial pathway)</td>
<td>↑ apoptosis</td>
<td>Programmed cell death</td>
<td>DCA induces apoptosis in glioblastoma and endometrial cancer models as mitochondrial remodeling is reversed</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/20463368/">(ref)</a></td>
</tr>

<tr>
<td>7</td>
<td>PUMA-mediated apoptotic priming</td>
<td>↑ PUMA-dependent sensitization</td>
<td>Lower apoptotic threshold</td>
<td>Endometrial cancer paper explicitly reports a PUMA-mediated component in DCA apoptosis sensitization</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/18423823/">(ref)</a></td>
</tr>

<tr>
<td>8</td>
<td>Hypoxia resistance axis (HIF-1α / PDK1)</td>
<td>↓ hypoxia-associated resistance (HIF-1α/PDK1 axis engaged)</td>
<td>Improved treatment responsiveness</td>
<td>DCA attenuates hypoxia-associated resistance in gastric cancer context with reported linkage to HIF-1α and PDK1</td>
<td><a href="https://www.sciencedirect.com/science/article/abs/pii/S0014482713005260">(ref)</a></td>
</tr>

<tr>
<td>9</td>
<td>Radiosensitization (hypoxic tumor cells)</td>
<td>↑ radiosensitivity (esp. under hypoxia)</td>
<td>Therapy potentiation</td>
<td>DCA increases ROS under hypoxia and enhances radiotherapy response in TNBC models</td>
<td><a href="https://www.mdpi.com/1422-0067/21/24/9367">(ref)</a></td>
</tr>

<tr>
<td>10</td>
<td>In vivo / translational anti-tumor activity (glioblastoma)</td>
<td>↓ tumor growth / ↓ proliferation (model-dependent)</td>
<td>Demonstrated anti-tumor effect</td>
<td>Glioblastoma study includes translational evidence that DCA can reverse tumor metabolic remodeling with anti-tumor effects</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/20463368/">(ref)</a></td>
</tr>

</table>